The New York Mets’ two-year, $22 million investment in A.J. Minter ultimately produced far less than the organization had hoped for. The left-handed reliever arrived with a strong reputation and the ability to become an important part of the bullpen, but injuries repeatedly interrupted his time in New York. By the time his Mets tenure came to an end, Minter had made only a limited number of appearances, leaving the club with a complicated evaluation of a signing that looked promising whenever he was actually available.
Minter’s contract included a player option for the second half of the deal, giving him additional control over his future while providing the Mets with a proven left-handed bullpen arm. The problem, however, was never simply whether Minter could pitch effectively. His ability was evident. The bigger concern was whether he could remain healthy long enough to make a meaningful impact. That question followed him throughout his short Mets tenure and ultimately became the defining feature of the signing.
The Mets signed Minter after he had already experienced injury problems with the Atlanta Braves in 2024, making the deal something of a calculated gamble. New York was betting that the veteran could overcome those issues and return to being the dependable late-inning reliever he had been during his best years in Atlanta. Instead, the injury concerns continued. Minter managed only 11 innings in 2025 before undergoing season-ending surgery, and his 2026 campaign also began late. When he finally returned, he pitched just 23 innings before the Mets eventually moved him, limiting the amount of time the organization had to properly assess his value.
On the surface, Minter’s numbers during his limited 2026 work were impressive. His 2.12 ERA suggested that he could still be an effective weapon out of the bullpen. However, the underlying statistics provided some reason for caution. His strikeout rate dropped by nearly two strikeouts per nine innings compared with previous levels, while his home-run rate increased by roughly 0.4 per nine innings. Those trends suggested that although the results remained respectable, Minter was not necessarily operating at the same dominant level he had shown earlier in his career.
That distinction became important when evaluating his role with the Mets. New York did not consistently use Minter as a primary late-inning weapon. Instead, he often occupied a middle- or lower-leverage role, particularly as the bullpen dealt with its own inconsistencies. In 2026, only 3.1 of his innings came in late-and-close situations, illustrating just how limited his opportunities were to influence games in the most critical moments. When he did receive those opportunities, the results were far less impressive, with opposing hitters batting .421 against him in those situations.
Minter also found himself competing with another established left-hander, Brooks Raley, for opportunities. Raley’s presence made it more difficult for Minter to establish himself as the unquestioned top left-handed option in the bullpen. Instead of becoming the obvious answer in high-pressure situations, Minter frequently remained part of a larger collection of relief options. His limited availability made that competition even more significant because the Mets could not consistently build their bullpen around him.
Still, the Mets were able to extract some value from the situation by turning Minter into a trade asset. Rather than allowing the veteran reliever to leave without receiving anything in return, New York moved him while he still had value as an experienced bullpen arm. That gave the organization at least some return on an investment that otherwise might have produced very little over the course of the contract.
That trade element prevents the signing from being viewed as a complete failure. The Mets were able to get something back for a player who had spent much of his New York tenure unavailable. The hope now is that the prospects or young players connected to the transaction can eventually provide major-league value or develop into trade assets themselves. Billy Amick and Bruin Agbayani therefore become part of the longer-term story surrounding the Minter signing.
Ultimately, the final assessment places the deal around a B, although the evaluation is complicated by the small sample size. An incomplete grade might actually be the most appropriate description because there simply was not enough playing time to make a definitive judgment about what Minter could have become in New York.
The Mets essentially received a short burst of production from a pitcher whose health prevented him from becoming a regular fixture. He was not a disaster when available, and his 2.12 ERA demonstrates that he could still pitch effectively. But the organization never got enough innings from him to justify viewing the signing as a major bullpen success.
Minter’s Mets tenure also stands in contrast with other left-handed relievers the organization has used. He never established himself as a dominant option in the way Aaron Loup once did, nor did he provide the sustained availability and longevity associated with Raley. Instead, his time in New York became defined by stretches of absence interrupted by relatively short periods of actual contribution.
The biggest lesson from the signing is therefore less about Minter’s talent and more about the risk of investing significant money in an injured player. The Mets clearly saw enough ability to commit $22 million over two years, but the availability they needed never materialized consistently. For a bullpen pitcher, especially one expected to handle important innings, durability can be nearly as valuable as raw effectiveness.
Minter leaves behind a Mets tenure that was difficult to categorize. He was effective enough to show why the team wanted him, but unavailable often enough to prevent that effectiveness from becoming a sustained contribution. His statistics were respectable, his role was limited, and his time in the organization was brief.
In the end, the Mets can take some comfort from turning him into a trade chip rather than receiving nothing in return. But the central issue remains unchanged: Minter had the ability to help the Mets, but he simply wasn’t available often enough to make the signing become what New York envisioned.
Leave a Reply